5-MeO-MiPT

5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine; miprocin) is a substituted tryptamine covered by the current NPSV generic Tryptamin-Verbindungen definition. It is not asserted as an individually named Suchtgift in the current SV schedules inspected. The NPSG regime principally criminalizes benefit-intended manufacture/import/export/transfer/supply with intended psychoactive use and provides seizure/forfeiture powers; medicines-law and Suchtmittelgesetz exclusions and lawful-use exceptions remain applicable. The canonical status is analog_covered because coverage is via a generic NPS/NPSV structural class rather than an individual narcotics-schedule listing.

For the identified pure compound 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine), current Canadian federal sources support an unscheduled/not-expressly-listed CDSA result: the complete current Schedules I-VI contain no exact entry and no generic tryptamine class rule, while Schedule III's 2C-phenethylamine class is structurally distinct from this indole tryptamine. This is not a determination for an unidentified or adulterated sample, does not address provincial or territorial law, and does not replace Health Canada's substance-status confirmation process for a particular substance or formulation; salts and analogue/derivative questions remain tied to the applicable schedule wording.

5-MeO-MiPT is expressly named in Finland's current consumer-market-banned psychoactive-substance annex, so the canonical category is restricted_other rather than prohibited as a narcotic, analog_covered, or unscheduled. The current control prohibits manufacture, import, storage, offering for sale and transfer, with statutory research and industrial exceptions. Section 5(2) does not itself state the blanket possession/use prohibition applicable to narcotics under section 5(1). The current consolidated narcotics schedule decree 543/2008 was independently inspected for exact-name and structural coverage; no 5-MeO-MiPT entry was found, while distinct entries such as 5-MeO-DMT remain separate.

Japan's current primary MHLW sources support canonicalStatus prohibited. The exact molecule is expressly listed as designated drug 5-MeO-MIPT (N-isopropyl-5-methoxy-N-methyltryptamine) and its salts in the current designated-drug list and consolidated ordinance. The separate current narcotic designation decree was checked and its similar 5-methoxy tryptamine entry is the distinct N,N-diisopropyl compound, not 5-MeO-MiPT. Under PMD Act Article 76-4, ordinary recreational manufacture, import, sale, transfer, possession, purchase, receipt and use are prohibited outside legally defined medical or other permitted uses.

For the identified pure compound 5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine), the current Legilux schedules inspected support an unscheduled/not-expressly-listed result: the 1974 psychotropic Annex ends at item 66 without 5-MeO-MiPT, the latest 2026 amendment adds only 2-MMC, NEP and 4-BMC, the separate narcotics list contains no applicable entry, and the 1997 Tables III/IV Annex contains no applicable tryptamine class. The 1974 Article 1 stereoisomer extension applies to substances actually listed and does not create a generic tryptamine analogue rule. Unscheduled is not an affirmative determination that every possession, import, sale, preparation or human-consumption transaction is lawful; other Luxembourg rules and fact-specific enforcement may apply, and a particular formulation or misidentified sample may require an authority determination.

The legacy 'prohibited along with other tryptamine derivatives as of January 2011' statement is corrected: the inspected consolidated Law No. 339/2005 annex names particular substances (including DMT, etriptamine, 5-MeO-DALT and other compounds) and applies its same-rules clause to isomers, ethers, esters and salts of listed substances; it does not create a generic tryptamine-derivative entry that expressly captures 5-MeO-MiPT. Because 5-MeO-MiPT was not found as a named substance in the inspected Table I, II or III text, no Law No. 339/2005 schedule or Table-I prohibition is asserted for the exact molecule. The residual Law No. 194/2011 framework applies to an otherwise unregulated product that is susceptible to psychoactive effects and can be used in place of a narcotic, psychotropic or nationally controlled substance: operations require authorization and are prohibited before authorization. Current penalty text must be distinguished from the 2014 republication: Law No. 58/2024 amended art. 16(1) to 3-10 years and disqualification from rights for knowing unauthorized operations; Law No. 172/2024 amended art. 16(2) to 1-5 years and disqualification where the person should or could have foreseen the psychoactive susceptibility, added 15-25 years and disqualification where death results, and made attempt punishable. These operation-based penalties do not establish that every act of possession or personal consumption of the exact unlisted molecule is a Law No. 339/2005 drug offence. The current legal treatment is therefore restricted_other, not an express prohibited scheduled-drug status; an authority's product-specific assessment under Law No. 194/2011 remains relevant.

As of 28 August 2026, the existing Turkey statement that 5-MeO-MiPT is classified as a drug and that possession, production, supply and import are prohibited is supported and normalized to canonicalStatus prohibited. The official Turkish Interior Ministry/General Directorate of Security 2013 Türkiye Uyuşturucu Raporu states that 60 new psychoactive substances were placed under Law No. 2313 by Council of Ministers Decision No. 2013/4827 (22 May 2013; published 25 June 2013 in Official Gazette No. 28688) and reproduces the Triptamin Grubu entry naming 5-MeO-MiPT and its full chemical name. The current official 2025 Türkiye Uyuşturucu Raporu identifies Law No. 2313 and TCK Articles 188, 190 and 191 as the principal framework, describes the EWS process for placing NPS under Law No. 2313, reports generic classification in Turkey since 2015, and reports 1,078 NPS under the law through 31 July 2025. No analogue inference is needed: 5-MeO-MiPT is individually named in the 2013/4827 annex. The 2025 report's generic-classification discussion does not establish additional analogue coverage for this exact substance. Under the current Ministry of Justice TCK publication, unauthorized manufacture/import/export falls under Article 188(1) (20–30 years' imprisonment and 2,000–20,000 days' judicial fine); domestic sale, offer, giving, dispatch, transport, storage, purchase, acceptance or possession falls under Article 188(3) (at least 10 years' imprisonment and 1,000–20,000 days' judicial fine); personal-use purchase, acceptance, possession or use falls under Article 191(1) (2–5 years' imprisonment), with Article 191(2)–(3) postponement, supervision, possible treatment and testing rules. Article 188(4)(a)'s half-increase categories include synthetic-cannabinoid, synthetic-cathinone, synthetic-opioid and amphetamine derivatives; this dossier does not attribute that enhancement to 5-MeO-MiPT merely because it is a tryptamine. A current consolidated individual-entry 2313 schedule PDF was not independently retrievable from the official Resmî Gazete archive endpoint because that endpoint failed certificate verification; therefore the historical exact annex is directly evidenced by the official Narkotik report, while the official 2025 Narkotik report evidences the continuing Law No. 2313/NPS framework through 31 July 2025. This does not resolve product-specific licensing, quantity, evidentiary or charging questions.

Supported replacement: 5-MeO-MiPT is expressly scheduled as a Schedule 1 dangerous drug in Queensland, and unlawful possession is a crime under the current Queensland Act. Federally, the current Criminal Code Regulations list the closely corresponding 5-MeO-DiPT as a border controlled drug and the Criminal Code treats qualifying analogues of listed border drugs as border controlled, with importing or exporting a border controlled drug criminalized by section 307.3. The Customs Schedule 4 and current Poisons Standard Schedule 9 searches found related named tryptamines but no exact 5-MeO-MiPT row; Customs uses a narrower chemically derived-and-regenerable derivative definition, while the Poisons Standard requires a fact-specific balanced derivative assessment. Australia is a federation, so the express Queensland result must not be generalized as an identical possession schedule in every State or Territory; the federal analogue pathway and any state or territory analogue rules remain dependent on the statutory elements and substance characterization.

5-MeO-MiPT is expressly listed in China's operative national non-pharmaceutical narcotic and psychotropic schedule. The current regulation permits non-pharmaceutical controlled substances only for authorized experimental research and prohibits ordinary production, commercial operation, use, storage and transport. The schedule also covers possible salts and stereoisomers unless otherwise specified. Import and export are governed by applicable separate laws under Article 2 of the regulation; this result does not infer an additional import/export rule beyond the sources cited.

The exact name 5-MeO-MiPT is not printed in the current Annex 2 named-entry sequence. However, the operative List I generic tryptamine provision expressly covers beta-(indol-3-yl)ethanamine derivatives bearing benzene-ring and/or amino-group substituents, and the fetched PubChem identity establishes that 5-MeO-MiPT has that core plus 5-methoxy, N-methyl and N-isopropyl substitution. List I is the prohibited category and § 5 bans ordinary cultivation, production, manufacture, import/export, distribution, advertising, transport, storage, transfer, acquisition, use and transit; quantity thresholds classify unlawful-circulation amounts and do not create a personal-use exception. The only identified authorization route is the narrow § 7 route for specified scientific, physical/chemical testing or training purposes.

5-MeO-MiPT (5-methoxy-N-methyl-N-isopropyltryptamine) is not independently named in the current Schedule 1 text, but its indole-ethylamine nucleus, N-methyl/N-isopropyl substitution, and 5-methoxy benzene substitution match the explicit Schedule 3 Part 7 DMT-analogue description. Section 2(1) makes a qualifying analogue a Class C controlled drug, so the appropriate canonical status is analog_covered rather than unscheduled. The statutory Medicines Act and approved-product exclusions remain applicable if the factual substance were a qualifying excluded product.